Bayer Grants4Apps® Dealmaker Berlin 2017

Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts for one full day. If there is a match, you will be invited to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Grants4Apps team has put together specific challenges, applicants are asked to address one or multiple of these challenges below. However, the team is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

The Challenges

Hemophilia

  • Empower hemophilia (bleeding disease) patients to individually adjust their treatment regimen to lead active lives.

Women's Health

  • Enabling earlier diagnosis of endometriosis.
  • Enhancing intrauterine device insertion training for providers.
  • Providing effective contraceptive counseling (face to face, remote or automated).
  • Improving comfort and experience during intrauterine device insertion for both providers & patients.
  • Simplifying the thread/placement check post-insertion of intrauterine devices.

Pulmonology

  • Improve identification of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients.
  • Improve adherence for an oral pulmonary hypertension treatment.
  • Innovative and efficient concepts for training staff to use a drug and device combination product in an intensive care unit setting.
  • Create awareness for limited outcome of standard of care treatment for pneumonia in the hospital.

Ophthalmology

  • Remote/mobile screening for Diabetic Retinopathy.
  • Remote monitoring of patients treated with anti-Vascular Endothelial Growth Factors (VEGFs).
  • Utilizing real-world evidence (RWE) to predict the need for anti-Vascular Endothelial Growth Factors (VEGFs)-injections.

Nephrology

  • Monitoring of chronic kidney disease (CKD).
  • Diagnosis of acute kidney injury.

Artificial Intelligence

  • Prediction of combination therapies for cancer.
  • Extract compound structures and Structure-Activity Relationship (SAR) data from patents.
  • Computer-assisted identification of new compounds for protein targets.
  • Develop analysis tool for in vivo experiments.

Data Analytics

  • Data analysis tools to systematically identify worldwide activities in Research & Development.
  • Deep Learning Research Services for health and life science data.
  • Transforming Electronic Health Records (EHR) data to analysis data sets.
  • Analyze drug labels to generate new insights.
  • Develop efficient analysis of large scientific literature corpi to generate insights.
  • How to implement prediction algorithms in hospital information systems.
  • Social Media use in pharma.

Clinical Trials

  • Patient identification and recruitment for clinical trials.
  • Improving the patient experience in clinical trials.
  • Develop a mobile platform for patients to report their health condition parameters.
  • Adherence improvement in (clinical trials OR) real life.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...